Welcome to our dedicated page for Bicycle Therapeutics SEC filings (Ticker: BCYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bicycle Therapeutics plc (NASDAQ: BCYC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC), and its filings offer detailed insight into its operations, governance and financial condition.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand how the company describes its Bicycle technology platform, clinical pipeline, collaboration revenue, research and development expenses, and other key aspects of its biotechnology business. Current reports on Form 8-K, such as those furnished for quarterly financial results and Board of Directors changes, provide timely information on material events, including clinical updates, cost realignment actions, and governance developments.
Because BCYC is listed on The Nasdaq Stock Market LLC through American Depositary Shares, its SEC filings also detail the securities registered under Section 12(b) of the Exchange Act and related listing information. Users interested in director and executive matters can look to proxy materials and 8-K items addressing appointments, compensation policies and inducement equity awards granted under the company’s 2024 Inducement Plan.
On Stock Titan, each BCYC filing is accompanied by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify disclosures related to clinical trial progress, collaboration agreements, and financial runway commentary. The platform also surfaces insider-related filings such as Form 4 when available, enabling users to monitor reportable transactions by directors and officers alongside the company’s broader SEC reporting history.
Bicycle Therapeutics PLC officer Michael Charles Ferguson reported selling a total of 1,772 Ordinary Shares in two transactions on April 2 and April 6, 2026, at weighted average prices around $4.91 and $5.05 per share.
According to the disclosure, these shares were sold solely to cover statutory tax withholding obligations arising from the vesting and settlement of RSUs under a mandatory “sell to cover” arrangement, rather than as discretionary open‑market sales. After these sales, Ferguson directly holds 96,136 Ordinary Shares.
Bicycle Therapeutics plc Chief Financial Officer Travis Alvin Thompson reported required sales of ordinary shares to cover taxes on vesting RSUs. On April 2, he sold 799 shares at a weighted average price of $4.91, from trades between $4.88 and $4.98. On April 6, he sold 102 shares at $5.05. The filing states these transactions were mandated "sell to cover" sales for statutory tax withholding and were not discretionary. After these sales, he directly holds 65,364 ordinary shares.
Bicycle Therapeutics plc Chief Operating Officer Jennifer Scott Perry sold a total of 1,408 ordinary shares of the company in early April 2026. The sales occurred on April 2 and April 6 at prices around $4.91–$5.05 per share. A portion of the shares was sold to cover statutory tax withholding obligations tied to the vesting and settlement of restricted stock units under a mandatory “sell to cover” arrangement, meaning those shares were not sold at her discretion. The filing also notes that one of the transactions was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025. Following these transactions, she directly holds 92,464 ordinary shares.
Bicycle Therapeutics CEO Kevin Lee disposed of 7,683 Ordinary Shares in mandated transactions tied to RSU vesting. The sales, executed as "sell to cover" for statutory tax withholding, occurred at weighted average prices around $4.91 and $5.05 per share. After these transactions, he continues to hold 611,313 Ordinary Shares directly.
Bicycle Therapeutics PLC chief scientific officer Michael Skynner reported small share sales tied to tax withholding on vested RSUs. On two April dates, a total of 2,404 ordinary shares were sold in the open market at weighted average prices around $4.91 and $5.05 per share to cover statutory tax obligations mandated by his award agreement. After these transactions, he continued to hold 159,562 ordinary shares directly.
The Board of Bicycle Therapeutics plc convenes its 2026 Annual General Meeting on June 17, 2026 to consider nine ordinary resolutions including re-election of two Class I directors, advisory "say-on-pay" votes, ratification and re-appointment of PricewaterhouseCoopers LLP as auditors, and approval of the directors’ remuneration policy.
The proxy materials (including the 2025 U.K. Annual Report and Form 10-K) will be made available to ordinary shareholders and ADS holders with record dates of June 15, 2026 (ordinary shareholders) and April 20, 2026 (ADS holders). Voting procedures, quorum rules and voting deadlines are described in the proxy statement.
BCYC insider reported planned and recent share sales. The filing lists 2,937 restricted shares to be sold on 04/02/2026 as equity compensation. It also reports prior sales by Alethia Young of 3,289 shares on 04/02/2026 for $22,358.62 and 4,334 shares on 01/05/2026 for $28,113.16.
BCYC submitted a Form 144 reporting proposed sales of restricted common stock. The filing lists a proposed sale of 3,187 restricted shares dated 04/02/2026 and a proposed sale of 111 restricted shares dated 04/03/2026. The broker listed is Stifel Nicolaus & Company Inc. and the securities are Common Stock traded on Nasdaq.
Notice of proposed resale by an affiliate. The filing reports proposed sales of Common Stock associated with equity compensation: 1,317 shares reported on 04/02/2026 (value shown $8,952.97) and 1,115 shares reported on 01/05/2026 (value shown $7,194.47). The excerpt also lists restricted stock amounts of 2,093 and 312 shares on 04/02/2026 and 04/03/2026, respectively.
BCYC insider reported stock dispositions and planned restricted-stock sales. The filing lists 3,187 shares of restricted common stock intended to be sold on 04/02/2026 and 512 shares on 04/03/2026. It also reports prior sales of 2,827 shares on 04/02/2026 for $22,052.71 and 2,367 shares on 01/05/2026 for $15,271.61. The filing shows 50,269,082 shares outstanding as of 04/02/2026.